Experienced in Infantile Neutropenia
Experienced in Infantile Neutropenia
Stony Brook Children's Service, University Faculty Practice Corporatio
2701 Sunrise Hwy, 
Islip Terrace, NY 

Overview

Laura Hogan is a Pediatric Hematologist Oncology provider in Islip Terrace, New York. Dr. Hogan is rated as an Experienced provider by MediFind in the treatment of Infantile Neutropenia. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Histiocytosis, Reticulohistiocytoma, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 17 peer reviewed articles and participating in 26 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Infantile Neutropenia.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in NY
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

STONY BROOK CHILDREN'S SERVICE, UNIVERSITY FACULTY PRACTICE CORPORATIO
2701 Sunrise Hwy, Islip Terrace, NY 11752

Additional Areas of Focus

Dr. Hogan has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


26 Clinical Trials

Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Renal Tumors Classification, Biology, and Banking Study
Key Adverse Events After Childhood Cancer
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
View 25 Less Clinical Trials
Similar Doctors
Distinguished in Infantile Neutropenia
Pediatric Hematology Oncology
Distinguished in Infantile Neutropenia
Pediatric Hematology Oncology

New York University

550 1st Ave, 
New York, NY 
 (40.6 miles away)
Languages Spoken:
English

Elizabeth Raetz is a Pediatric Hematologist Oncology provider in New York, New York. Dr. Raetz is rated as a Distinguished provider by MediFind in the treatment of Infantile Neutropenia. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Adult T-Cell Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Distinguished in Infantile Neutropenia
Pediatric Hematology Oncology
Distinguished in Infantile Neutropenia
Pediatric Hematology Oncology
1275 York Ave, 
New York, NY 
 (39.7 miles away)
Languages Spoken:
English

Ira Dunkel is a Pediatric Hematologist Oncology provider in New York, New York. Dr. Dunkel is rated as an Elite provider by MediFind in the treatment of Infantile Neutropenia. His top areas of expertise are Retinoblastoma, Diffuse Midline Glioma H3 K27M-Mutant, Glioma, and Brain Stem Cancer.

Eleny C. Romanos
Advanced in Infantile Neutropenia
Pediatric Hematology Oncology | Pediatrics
Advanced in Infantile Neutropenia
Pediatric Hematology Oncology | Pediatrics

Northwell Health Florina Cancer Center

475 Seaview Avenue, 
Staten Island, NY 
 (47.9 miles away)
Languages Spoken:
English

Eleny Romanos-Sirakis, MD, MS, FAAP is a board-certified specialist in pediatric hematology/oncology and is the Director of Pediatric Hematology and Oncology at Staten Island University Hospital (SIUH). She has advanced and expanded the care for patients undergoing evaluation and treatment for cancer and blood disorders at SIUH. She provides comprehensive care to patients from infancy to 21 years of age. Dr. Romanos provides clinical evaluations and treatments for a wide variety of hematology and oncology concerns, including anemia, low or high white blood cell counts, low or high platelet counts, bleeding disorders, clotting disorders, sickle cell disease, thalassemia, hemoglobinopathies, enlarged lymph nodes, bone tumors, histiocytosis, leukemia, lymphoma, and solid tumors.Dr. Romanos came to SIUH from NYU Langone Medical Center in Manhattan, where she specialized in pediatric cancers and blood disorders. She brings this expertise to Staten Island and provides this high-quality specialty care locally, removing the need for patients to leave Staten Island for evaluations and treatments. She understands that all children have unique needs and is dedicated to providing personalized care to meet the individualized needs of her patients and their entire families. She has specialized and extensive training in the care of children with special needs; Dr Romanos and her entire team work to ensure that the needs of each family are met in this personalized approach to treating each child. Families' specific needs or requests should be communicated to the office staff when scheduling appointments; every effort will be made to accommodate each patient and family.Providing optimal care and assessments, while maximizing patient and family quality of life, is of highest priority for Dr. Romanos. She has additional training in pediatric pain management and was actively involved in developing the SIUH Pediatric Comfort Campaign to minimize pain for children undergoing procedures and improve overall pain management for pediatric patients. She is committed to education and research at SIUH; she is actively involved in further advancing research at SIUH as the chair of the pediatric research and scholarship committee. She is also an active committee member of the American Society of Pediatric Hematology/Oncology and the American Academy of Pediatrics.Dr. Romanos is a native New Yorker and is dedicated to providing personalized and high-quality care to all of her patients. Dr. Romanos is rated as an Advanced provider by MediFind in the treatment of Infantile Neutropenia. Her top areas of expertise are Shwachman-Diamond Syndrome, Infantile Neutropenia, Sickle Cell Disease, and Febrile Neutropenia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hogan's expertise for a condition
ConditionClose
      View All 20 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile